Antiplatelet and Anticoagulant Agents in Heart Failure. Current Status and Future Perspectives.

JACC: Heart Failure

Volumn 2, Issue 1, 2014, Pages 1-14

  Gurbel, Paul A ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

Anticoagulant; Antiplatelet; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; CYCLOOXYGENASE 1; DABIGATRAN; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; IRBESARTAN; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; TICAGRELOR; WARFARIN; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; EMBOLISM; ENZYME SYNTHESIS; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MONOTHERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VENOUS STASIS; VENOUS THROMBOEMBOLISM; COMPLICATION; CORONARY THROMBOSIS; FORECASTING; META ANALYSIS (TOPIC); MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; STROKE; TREATMENT OUTCOME; ARTERY EMBOLISM; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; TREATMENT RESPONSE; VEIN EMBOLISM; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CORONARY THROMBOSIS; FIBRINOLYTIC AGENTS; FORECASTING; HEART FAILURE; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84892981695     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.07.007     Document Type: Review

References (82)

1. Go A.S., Mozaffarian D., Roger V.L., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. Zannad F., Stough W.G., Regnault V., et al. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol 2013, 167:1772-1782.
3. Witt B.J., Gami A.S., Ballman K.V., et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. JCard Fail 2007, 13:489-496.
4. Pullicino P.M., Halperin J.L., Thompson J.L. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000, 54:288-294.
5. Vandvik P.O., Lincoff A.M., Gore J.M., et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e637S-e668S. American College of Chest Physicians.
6. Gurbel P.A., Bliden K.P., Hayes K.M., Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004, 2:535-545.
7. Mann K.G. Thrombin generation in hemorrhage control and vascular occlusion. Circulation 2011, 124:225-235.
8. O'Connor C.M., Gurbel P.A., Serebruany V.L. Usefulness of soluble and surface bound P-selectin in detecting heightened platelet activity in patients with chronic heart failure. Am J Cardiol 1999, 83:1345-1349.
9. Serebruany V., McKenzie M., Meister A., et al. Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). Eur J Heart Fail 2002, 4:461-467.
10. De Lorenzo F., Saba N., Kakkar V.V. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention. Drugs 2003, 63:565-576.
11. O'Connor C.M., Gurbel P.A., Serebruany V.L. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999, 83:1345-1349.
12. Stumpf C., Lehner C., Eskafi S., et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003, 5:629-637.
13. Alehagen U., Dahlstrom U., Lindahl T.L. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004, 92:1250-1258.
14. Molvarec A., Rigó J., Bõze T. Increased plasma von Willebrand factor antigenlevels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009, 101:305-311.
15. Nawroth P.P., Stern D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. JExp Med 1986, 163:740-745.
16. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. NEngl J Med 1990, 323:236-241.
17. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
18. Lowe G.D. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003, 33:455-457.
19. Nesbitt W.S., Mangin P., Salem H.H., Jackson S.P. The impact of blood rheology on the molecular and cellular events underlying arterial thrombosis. JMol Med 2006, 84:989-995.
20. Lopez J.A., Kearon C., Lee A.Y. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004, 439-456.
21. Kroegel C., Reissig A. Principle mechanisms underlying venous thromboembolism; epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003, 70:7-30.
22. Chirinos J.A., Heresi G.A., Velasquez H., et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. JAm Coll Cardiol 2005, 45:1467-1471.
23. Mackman N. New insights into the mechanisms of venous thrombosis. JClin Invest 2012, 122:2331-2336.
24. Carpio F.D., Chirinos J.A., Jimenez J. Endothelial, platelet and leukocyte activation in patients with congestive heart failure. JCard Fail 2004, 10:S55-S65.
25. Bourassa M.G., Gurne O., Bangdiwala S.I., et al. Natural history and patterns of current practice in heart failure. JAm Coll Cardiol 1993, 22:14A-19A.
26. Zannad F., McMurray J.J., Krum H., et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364:11-21.
27. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
28. Freudenberger R.S., Hellkamp A.S., Halperin J.L., et al. SCD-HeFT Investigators. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007, 115:2637-2641.
29. Vemmos K., Ntaios G., Savvari P., et al. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail 2012, 14:211-218.
30. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. JStroke Cerebrovasc Dis 1995, 5:147-157. Stroke Prevention in Atrial Fibrillation Investigators.
31. Ahmad Y., Lip G.Y., Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther 2012, 10:1471-1480.
32. Mehta J., Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation 1979, 60:497-503.
33. Lip G.Y., Rasmussen L.H., Skjøth F., et al. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open 2012, 2(4).
34. Alberts V.P., Bos M.J., Koudstaal P., et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010, 25:807-812.
35. Loh E., Sutton M.S., Wun C.C., et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. NEngl J Med 1997, 336:251-257.
36. Piazza G., Goldhaber S.Z., Lessard D.M., et al. Venous thromboembolism in heart failure: preventable deaths during and after hospitalization. Am J Med 2011, 124:252-259.
37. Khoury H., Welner S., Kubin M., et al. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients inEurope show underutilisation of preventive therapies. Thromb Haemost 2011, 106:600-608.
38. Dunkman W.B., Johnson G.R., Carson P.E., Bhat G., Farrell L., Cohn J.N. Incidence of thromboembolic events in congestive heart failure. Circulation 1993, 87. the V-HeFT VA Cooperative Studies Group, VI94-VI101.
39. Gurbel P.A., Tantry U.S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012, 125:1276-1287.
40. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. JAm Coll Cardiol 2005, 46:1820-1826.
41. Gurbel P.A., Tantry U.S. Combination antithrombotic therapies. Circulation 2010, 121:569-583.
42. Diener H.C., Bogousslavsky J., Brass L.M., et al. MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
43. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673. ESPRIT Study Group.
44. Sacco R.L., Diener H.C., Yusuf S., et al. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. NEngl J Med 2008, 359:1238-1251.
45. Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. Antithrombotic Trialists' (ATT) Collaboration.
46. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
47. You J.J., Singer D.E., Howard P.A., Lane D.A., et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e531S-e575S.
48. Eriksson N., Wadelius M. Prediction of warfarin dose: why, when and how?. Pharmacogenomics 2012, 13:429-440.
49. Hylek E., Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120:897-902.
50. Oden A., Fahlen M., Hart R.G. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006, 117:493-499.
51. De Caterina R., Husted S., Wallentin L., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. JAm Coll Cardiol 2012, 59:1413-1425. Coordinating Committee.
52. Weitz J.I. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011, 127:S5-S12.
53. Lip G.Y., Ponikowski P., Andreotti F., et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012, 14:681-695. ESC Task Force.
54. Wishart J.H., Chapman C.B. Dicumarol therapy in congestive heart failure. NEngl J Med 1948, 239:702-704.
55. Harvey W.P., Finch C.A. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. NEngl J Med 1950, 242:208-211.
56. Griffith G.C., Stragnell R., Levinson D.C. Astudy of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952, 37:867-887.
57. Al-Khadra A.S., Salem D.N., Udelson J.E., et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. JAm Coll Cardiol 1998, 31:749-753.
58. Leor J., Reicher-Reiss H., Goldbourt U., et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. JAm Coll Cardiol 1999, 33:1920-1925.
59. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997, 79:115-119.
60. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912. ACTIVE Writing Group of the ACTIVE Investigators.
61. Cleland J.G.F., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic therapies for patients with heart failure. Am Heart J 2004, 148:157-164.
62. Cokkinos D.V., Haralabopoulos G.C., Kostis J.B., Toutouzas P.K. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006, 8:428-432.
63. Massie B.M., Collins J.F., Ammon S.E., et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009, 119:1616-1624. WATCH Trial Investigators.
64. Homma S., Thompson J.L.P., Pullicino P.M., et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. NEngl J Med 2012, 366:1859-1869. WARCEF Investigators.
65. Eikelboom J.W., Connolly S.J. Warfarin in heart failure. NEngl J Med 2012, 366:1936-1938.
66. Homma S. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF) trial. Paper presented at: Heart Failure Society ofAmerica2012 Scientific Meeting; September 10, 2012; Seattle, WA.
67. Hopper I., Skiba M., Krum H. Updated meta-analysis on anti-thrombotic therapy in patients with heart failure and sinus rhythm. Eur J Heart Fail 2013, 15:69-78.
68. Kumar G., Goyal M.K. Warfarin versus aspirin for prevention of stroke in heart failure: a meta-analysis of randomized controlled clinical trials. JStroke Cerebrovasc Dis 2013, 22:1279-1287.
69. Avellana P., Segovia J., Ferrero A., Vázquez R., et al. Anticoagulation therapy in patients with heart failure due to systolic dysfunction and sinus rhythm: analysis of REDINSCOR registry. Rev Esp Cardiol 2012, 65:705-712.
70. Miller C.S., Grandi S.M., Shimony A., et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110:453-460.
71. Banerjee A., Lane D.A., Torp-Pedersen C., Lip G.Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012, 107:584-589.
72. Dangas G., Mehran R., Feit F., et al. Impact of bivalirudin therapy on mortality in patients with high risk features undergoing PCI: a patient-level pooled analysis from the REPLACE-2, ACUITY, and HORIZONS-AMI trials (abstr). Eur Heart J 2011, 32(Suppl):232-233.
73. Kohli P., Chakrabarti A., Bansilal S., et al. Reduction in mortality from thrombin inhibition in CHF patients: results from the premier hospital database (abstr.). Eur Heart J 2013, 33(Suppl 1):393. on behalf of TIMI Study Group.
74. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
75. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
76. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. NEngl J Med 2011, 365:699-708. APPRAISE-2 Investigators.
77. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
78. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med 2012, 366:9-19. ATLAS ACS 2-TIMI 51 Investigators.
79. Gheorghiade M., Thyssen A., Zolynas R., et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. JHeart Lung Transplant 2011, 30:218-226.
80. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869. ESC Committee for Practice Guidelines.
81. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure Practice guideline. JCard Fail 2010, 16:e1-e194. Heart Failure Society of America.
82. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; developed in collaboration with the International Society for Heart and Lung Transplantation. JAm Coll Cardiol 2009, 53:e1-e90.